Bevacizumab Against Recurrent Retinal Detachment

Phase 2CompletedNCT02192970

University of Wisconsin, Madison101 enrolled

Overview

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

101

Conditions

Retinal Detachment Proliferative Vitreoretinopathy

Interventions

BevacizumabDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Eyes with rhegmatogenous retinal detachment Exclusion Criteria: * Presence of PVR * Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy. * Recent intravitreal injection of an anti-VEGF agent less than 3 months prior * Secondary retinal detachment repair * Use of silicone oil as tamponade agent * Patients less than 18 years of age * Pregnancy * Known allergy or contraindication to intravitreal bevacizumab

Locations (1)

University of Wisconsin

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery

Complete success of primary vitrectomy surgery, defined as retinal re-attachment without the need for any additional surgical procedures.

Time frame: 6 months

Secondary Outcomes

Number of Participants (or Chart Reviews) With Presence of Proliferative Vitreoretinopathy

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.